Gayathri R. Devi - Publications

Pathology Duke University, Durham, NC 
Cell Biology

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Sauer SJ, Tarpley M, Shah I, Save AV, Lyerly HK, Patierno SR, Williams KP, Devi GR. Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis. 38: 252-260. PMID 28426875 DOI: 10.1093/carcin/bgx003  0.32
2013 Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Annals of Surgery. 258: 879-86. PMID 23657083 DOI: 10.1097/SLA.0b013e318292919e  0.32
2013 Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunology, Immunotherapy : Cii. 62: 1293-301. PMID 23624851 DOI: 10.1007/s00262-013-1400-3  0.32
2013 Nair S, Aldrich AJ, McDonnell E, Cheng Q, Aggarwal A, Patel P, Williams MM, Boczkowski D, Lyerly HK, Morse MA, Devi GR. Immunologic targeting of FOXP3 in inflammatory breast cancer cells. Plos One. 8: e53150. PMID 23341929 DOI: 10.1371/journal.pone.0053150  0.32
2013 Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Research and Treatment. 137: 359-71. PMID 23225169 DOI: 10.1007/s10549-012-2352-6  0.32
2012 Rangwala F, Williams KP, Smith GR, Thomas Z, Allensworth JL, Lyerly HK, Diehl AM, Morse MA, Devi GR. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. Bmc Cancer. 12: 402. PMID 22963400 DOI: 10.1186/1471-2407-12-402  0.32
2012 Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Molecular Cancer Therapeutics. 11: 1518-27. PMID 22508521 DOI: 10.1158/1535-7163.MCT-11-0787  0.32
2012 Osada T, Berglund P, Morse MA, Hubby B, Lewis W, Niedzwiecki D, Yang XY, Hobeika A, Burnett B, Devi GR, Clay TM, Smith J, Kim Lyerly H. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. Cancer Immunology, Immunotherapy : Cii. 61: 1941-51. PMID 22488274 DOI: 10.1007/s00262-012-1248-y  0.32
2012 Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, Dewhirst MW, Devi GR. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Research and Treatment. 132: 109-19. PMID 21559822 DOI: 10.1007/s10549-011-1568-1  0.32
2011 Ye X, Fels D, Tovmasyan A, Aird KM, Dedeugd C, Allensworth JL, Kos I, Park W, Spasojevic I, Devi GR, Dewhirst MW, Leong KW, Batinic-Haberle I. Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radical Research. 45: 1289-306. PMID 21859376 DOI: 10.3109/10715762.2011.616199  0.32
2011 Thomas ZI, Gibson W, Sexton JZ, Aird KM, Ingram SM, Aldrich A, Lyerly HK, Devi GR, Williams KP. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. British Journal of Cancer. 104: 1575-86. PMID 21505458 DOI: 10.1038/bjc.2011.133  0.32
2010 Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. The Journal of Clinical Investigation. 120: 3234-41. PMID 20679728 DOI: 10.1172/JCI42672  0.32
2010 Aird KM, Ghanayem RB, Peplinski S, Lyerly HK, Devi GR. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Molecular Cancer Therapeutics. 9: 1432-42. PMID 20406946 DOI: 10.1158/1535-7163.MCT-10-0160  0.32
2010 Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. International Journal of Cancer. 126: 2893-903. PMID 19856307 DOI: 10.1002/ijc.24995  0.32
2009 Iversen PL, Aird KM, Wu R, Morse MM, Devi GR. Cellular uptake of neutral phosphorodiamidate morpholino oligomers. Current Pharmaceutical Biotechnology. 10: 579-88. PMID 19619124 DOI: 10.2174/138920109789069279  0.32
2008 Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, Lyerly HK, Devi GR. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression Molecular Cancer Therapeutics. 7: 38-47. PMID 18202008 DOI: 10.1158/1535-7163.MCT-07-0370  0.32
2007 Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. Journal of Translational Medicine. 5: 42. PMID 17822557 DOI: 10.1186/1479-5876-5-42  0.32
Show low-probability matches.